The Persistence of Predictable Inspection Findings
Health authority inspection findings in the pharmaceutical and medical device sector are not unpredictable. The same categories appear in FDA Form 483 observations, EMA GMP non-compliance reports, and MHRA GxP inspection findings year after year. In 2024 and 2025, three categories — data integrity, CAPA effectiveness, and computerised system controls — appeared in over 70% of inspections with significant findings across all three jurisdictions.
This whitepaper analyses 2024–2025 inspection data across all three major health authorities and provides the site-level remediation framework for each finding category.
The Six Most Common Finding Categories
Category 1 — Data integrity: audit trail and ALCOA+ failures
Data integrity remains the dominant inspection finding category globally. In 2024–2025, the most common observations relate to: audit trail disabling (deliberate or through misconfiguration), shared user accounts for electronic systems, manual data transcription without second-person verification, backdating of records, and failure to investigate out-of-specification results before retesting.
A significant 2025 shift: inspectors are increasingly finding data integrity failures in systems under electronic controls — LIMS, MES, QMS platforms — not only in paper-based systems. The assumption that electronic systems are inherently ALCOA+ compliant is false and has led organisations to reduce oversight of electronically generated data.
Category 2 — CAPA effectiveness
CAPA ineffectiveness is the second most common major finding in 2024–2025. The dominant finding has evolved: no longer the absence of effectiveness checks, but the presence of nominal effectiveness checks that confirm implementation without confirming outcome. Verifying that an operator was retrained does not verify that the behaviour that caused the deviation has changed.
Category 3 — Computerised system validation gaps
Computerised system validation gaps increasingly relate to AI and machine learning systems deployed in GxP environments without adequate validation frameworks. Systems validated under Annex 11 principles but not extended to address AI-specific requirements — intended use boundaries, training data governance, continuous performance monitoring — are generating observations as inspectors become specifically trained in AI system assessment.
EMA inspectors in 2025 are routinely asking to see AI system inventories and validation documentation for each system. Organisations without formal AI system inventories are receiving observations regardless of individual AI system validation quality.
Category 4 — Change control
Change control failures in 2024–2025 frequently relate to AI system updates — model retraining or vendor-supplied model updates applied without change control assessment. The observation is not about the model update itself — it is about the failure to assess the change impact before implementation, exactly as would be required for any other computerised system modification.
Category 5 — Laboratory controls
Laboratory control observations in 2024–2025 concentrate on OOS result investigation: investigations that do not follow documented procedures, investigations that conclude without genuine root cause identification, and second-sample testing conducted before completing Phase 1 investigation. FDA Warning Letters for OOS investigation failures have increased year-on-year since 2022.
Category 6 — Training effectiveness
Training record compliance — completing training on schedule — is generally well-managed. Training effectiveness — verifying that training has changed behaviour or increased competence — is consistently found to be inadequate. Competency assessments that are checkbox exercises rather than genuine skill verification are a frequent finding.
Remediation Priority Framework
| Finding Category | Root Cause | Priority | Timeline |
|---|---|---|---|
| Data integrity | System configuration gaps + cultural tolerance for shortcuts | Critical — before next inspection | 4–8 wks config; 3–6 months culture |
| CAPA effectiveness | Superficial root cause analysis + nominal effectiveness checks | High — programme redesign | 8–16 weeks |
| Computerised systems / AI | AI systems without extended validation framework | High — Annex 22 from 2026 | 6–18 months for full programme |
| Change control | AI updates not captured in change control scope | Medium | 4–8 weeks |
| Laboratory controls | OOS investigation not followed consistently | Medium | 4–8 weeks |
| Training effectiveness | Competency assessment not genuine | Medium | 8–12 weeks |
GxP inspection readiness specialists. Assessment within 48 hours.